摘要
Irritable bowel syndrome is not a life-threatening disease, yet it significantly affects the quality of life and contributes to economic loss. It is estimated that even up to 45% of the world’s population can suffer from the disease. The first attempts to diagnose irritable bowel syndrome were made at the end of the 19th century; however, establishing appropriate diagnostic criteria and treatment methods is still ongoing. To date, little is known about the etiology of irritable bowel syndrome; however, growing attention is drawn to the intestinal microbiota as a factor in the disease development. For this reason, researchers have conducted many studies on therapies that modulate the microbiota, among which probiotics, prebiotics, and synbiotics are widely studied. To date, most studies have examined probiotics; however, there are also several studies demonstrating the efficacy of prebiotics and synbiotics. The aim of this review was to summarize findings on the usefulness of probiotics, prebiotics, and synbiotics in the treatment of irritable bowel syndrome.
摘要译文
肠易激综合征不是危及生命的疾病，但它显着影响了生活质量并有助于经济损失。据估计，甚至占世界人口的45％可患有该疾病。第一次诊断肠易激综合征的尝试是在19世纪末进行的;然而，建立适当的诊断标准和治疗方法仍在进行。迄今为止，关于肠易激综合征的病因少知之甚少;然而，将肠道微生物群作为疾病发展的一个因素将不断的注意力吸引。因此，研究人员对调节微生物群的疗法进行了许多研究，其中益生菌，益生菌和同步是广泛研究的。迄今为止，大多数研究都研究过益生菌;然而，还有几项研究证明了益生元和同步的疗效。本综述的目的是总结对益生菌，益生元和协会治疗肠易激综合征的有用性的结果。
Agnieszka Chlebicz-Wójcik[ [*];Katarzyna Śliżewska[ [*]. Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review[J]. Biomolecules, 2021,11(8): 1154